Products
Suppliers
Sourcing Requests

Post Sourcing Request Exhibition

Home
Products
Supplier
E-Trade Season
Content Hub
Industry Insights
Service & Membership
For Supplier

My Account

My Online Store

My EZSourcing

View Sourcing Requests

Customer Service
For Buyer

Search Products & Suppliers
Products Directory Suppliers Discovery Post EZSourcing
Service
Buyer Sourcing Event Contact Us
Quick links
My Favorites Recent Visit History

996热re视频精品视频这里,国产又色又爽又高潮免费,精品自拍亚洲一区在线,久久久综合九色合综,国产精品亚洲综合一区在线观看

<sup id="qvkqj"></sup>

<cite id="qvkqj"></cite>

You are here: Industry Insights > Market News > Janssen's Stelara shows promise across two dosages in ulcerative colitis

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Jackfruit Powder

Jackfruit Powder

Pineapple Powder

Pineapple Powder

Musang King Durian Powder

Musang King Durian Powder

Noni Enzyme Powder

Noni Enzyme Powder

VITAMIN B12

hydraulic column packer/protein chromatography column/prepacked gel column packer

hydraulic column packer/protein chromatography column/prepacked gel column packer

Janssen's Stelara shows promise across two dosages in ulcerative colitis

pharmafileNovember 20, 2018

Tag: Janssen , Stelara , IBDQ

Favorites

Previous:Menlo Therapeutics' cough drug fails to meet primary endpoint in phase II trial

Next:New hospital-led organisation aims to tackle drug pricing problem by manufacturing generic drugs

Related News

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

PharmaSourcesMay 16, 2025

InnoCare Pharma announced today that the first patient has been dosed in the Phase II/III clinical trial of its novel TYK2 inhibitor, Soficitinib (ICP-332), for the treatment patients with non-segmental vitiligo in China.

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

PR NewswireMay 12, 2025

Illuccix China Phase 3 Study Completes Enrolment

PR NewswireMay 13, 2025

Janssen's Stelara shows promise across two dosages in ulcerative colitis | Pharmasources.com

iotaMotion Announces First Use of Robotic-Assistedmpla Cochlear Int Technology Outside the U.S. as Part of Clinical Investigation in Switzerland

PR NewswireMay 14, 2025

iotaMotion, Inc., a leader in robotic-assisted systems for cochlear implant surgery, announced the first use of the iotaSOFT? Insertion System outside of the United States.

You may like
More>>

PHENOXYMETHYL PENICILLIN POTASSIUM

PHENOXYMETHYL PENICILLIN POTASSIUM

LINCOMYCIN HCL

GENTAMYCIN SULPHATE macrolides

GENTAMYCIN SULPHATE macrolides

CEFALEXINE cephalosporins

CEFALEXINE cephalosporins

CEFRADINE cephalosporins

CEFRADINE cephalosporins

CEFADROXIL cephalosporins

CEFADROXIL cephalosporins

CEFIXIME cephalosporins

CEFIXIME cephalosporins

CEFATHIAMIDINE cephalosporins

CEFATHIAMIDINE cephalosporins

CEFMINOX SODIUM cephalosporins

CEFMINOX SODIUM cephalosporins

CEFOXITIN SODIUM cephalosporins

CEFOXITIN SODIUM cephalosporins

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

About Us: About PharmaSources; Terms of Service; Privacy Policy; Event Data Sharing Notice; Intellectual Property; Media Partners

Buy: Search Products; Post Sourcing Requests; Search Suppliers; CAS Search

Sell: Member Application; Advertising; Post Products; EZSourcing

Events: CPHI China; PMEC China; Conferences; Search Events

Help: FAQ; Contact Us; Feedback

Copyright 2006-2025 Shanghai Sinoexpo Informa Markets International Exhibition Co. Ltd (All Rights Reserved) 滬ICP備05034851號-182 滬公網(wǎng)安備31010402010101號
Links：
CCCMHPIE SJGLE.com JJGLE.COM JDGLE.COM XIUGLE.COM DENGGLE.COM HPGLE.COM
Follow Us：
Pharma Sources Insight January 2025

PharmaSources Customer Service

^{<blockquote id="1u49c"><rt id="1u49c"></rt></blockquote>}